Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO Seeks More Aggressive Approach On Limiting Safety Data Collection

Executive Summary

The American Society of Clinical Oncology says FDA’s draft guidance on targeted safety data collection is too conservative and inconsistent with the agency’s recommendations from a 2001 guidance on cancer drug clinical trials. ASCO requests the two guidances be harmonized to eliminate the potential for confusion among sponsors and clinical trial investigators.

Advertisement

Related Content

FDA Oncology Panel To Weigh Independent Review Of PFS Event Subset
FDA’s Guide For Selectively Collecting Safety Data
Targeted Safety Data Collection Needs International Agreement, Industry Tells FDA
Targeted Safety Data Collection Needs International Agreement, Industry Tells FDA
FDA Opts For Full, Rather Than Accelerated, Approval Of GSK’s Votrient In Sarcoma
Merck, GSK Sarcoma Drugs Bring Different Efficacy Stories To FDA Panel Review

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054421

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel